10/01/2025
โจ Today is World Urticaria Day (UDAY) โ a day to stand with millions who face persistent itching, swelling, and unpredictable flares due to urticaria. The 2025 theme, โUnmet Needs โ The Path Forward for Urticaria,โ highlights how much work still lies ahead in diagnosis, access, and new treatments. โโ
โโ
๐ Chronic spontaneous urticaria (CSU) is a particularly challenging form: daily wheals and angioedema without a clear trigger lasting 6+ weeks. Standard therapies often fall short, leaving many patients with lingering symptoms and impaired quality of life.โโ
โโ
๐ Enter RHAPSIDOยฎ (remibrutinib) โ the first FDA-approved oral therapy for CSU. Clinical trials show that some patients see improvements in as little as 2 weeks, and 1 in 3 achieve complete relief of hives and itch within 3 months!โโ
โโ
It works via a novel mechanism (BTK inhibition) rather than just blocking histamine, and it carries a favorable safety profile with no required lab monitoring! โโ
โโ
๐ฃ Letโs use to amplify patient voices, share experiences, highlight unmet needs, and celebrate steps forward like RHAPSIDOยฎ. Awareness leads to research, better care, and renewed hope.
